Vanderbilt University: Potential AML Therapy Induces Leukemic Stem Cell Death
January 05, 2024
January 05, 2024
NASHVILLE, Tennessee, Jan. 5 (TNSres) -- Vanderbilt University Medical Center issued the following news:
By Tom Wilemon
A potential therapy for acute myeloid leukemia (AML) targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.
The potential therapy, NC525, is an agonist antibody to the leukocyte-associated immunoglobulin-like receptors (LAIR-1), which have abnormally elevated expressio . . .
By Tom Wilemon
A potential therapy for acute myeloid leukemia (AML) targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.
The potential therapy, NC525, is an agonist antibody to the leukocyte-associated immunoglobulin-like receptors (LAIR-1), which have abnormally elevated expressio . . .